Graybug Vision to Host Virtual R&D Day on March 30, 2022
March 21, 2022 16:30 ET
|
Graybug Vision, Inc.
BALTIMORE, March 21, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
$616.31Mn by 2028, Optical Coherence Tomography Angiography Equipment Market Size, 6.8% CAGR Lead by Tabletop Type - Exclusive Research Report by The Insight Partners
March 17, 2022 07:00 ET
|
The Insight Partners
New York, March 17, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Optical Coherence Tomography Angiography Equipment Market Forecast to 2028 - COVID-19 Impact and...
Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments
March 10, 2022 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, March 10, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Global Bionic Eye Market Research Report 2021 Featuring Nidek, Nano Retina, MetaModa, Pixium Vision, Monash Vision, iBionics & Optobionics
March 10, 2022 04:03 ET
|
Research and Markets
Dublin, March 10, 2022 (GLOBE NEWSWIRE) -- The "Global Bionic Eye Market, By Type (Implant v/s External), By Technology (Electronic v/s Mechanical), By End User (Hospitals, Ophthalmic Clinics,...
ONL Therapeutics Appoints Sushanta Mallick as Chief Development Officer
February 09, 2022 07:00 ET
|
ONL Therapeutics
ANN ARBOR, Mich., Feb. 09, 2022 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal...
Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline
January 20, 2022 07:30 ET
|
Graybug Vision, Inc.
BALTIMORE, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
ONL Therapeutics Closes 2nd Tranche of $46.9 Million Series B Financing Upon Achieving ONL1204 Development Milestones
January 13, 2022 07:00 ET
|
ONL Therapeutics
– Lead candidate ONL1204 Ophthalmic Solution has advanced into chronic indications of open-angle glaucoma (OAG) and geographic atrophy (GA) associated with age-related macular degeneration (AMD) – –...
Vitrectomy Devices Market Size ($2,003.24Mn by 2028) Lead by Vitrectomy Machines (6.5% CAGR) Impact of Coronavirus Outbreak and Global Analysis & Forecast by TheInsightPartners.com
November 29, 2021 06:48 ET
|
The Insight Partners
New York, Nov. 29, 2021 (GLOBE NEWSWIRE) -- According to our new research study on Vitrectomy Devices Market Size, Share, Revenue, Growth, Trends, Forecast to 2028 - COVID-19 Impact and Global...
Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 15, 2021 16:05 ET
|
Graybug Vision, Inc.
BALTIMORE, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of...
Eyenuk Announces Publication of Strong EyeArt® Pivotal Clinical Trial Results in JAMA Network Open
November 15, 2021 14:38 ET
|
Eyenuk, Inc.
LOS ANGELES, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Eyenuk, Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye...